Twoja Przychodnia Poznańskie Centrum Medyczne Sp. z o.o.
- Address
- lock Available on a paid plan
Twoja Przychodnia Poznańskie Centrum Medyczne - Autoimmune & Inflammatory Disease Research Center
Twoja Przychodnia Poznańskie Centrum Medyczne is a distinguished clinical research facility in Poland specializing in autoimmune and inflammatory disorders. The center demonstrates extensive expertise in conducting Phase 2 and Phase 3 clinical trials across a diverse spectrum of rheumatological, gastroenterological, and dermatological conditions, with particular emphasis on novel biologic and targeted therapies.
- Rheumatological disorders including psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, Sjögren's disease, and systemic sclerosis-associated interstitial lung disease
- Inflammatory bowel diseases, particularly Crohn's disease and ulcerative colitis, with focus on both induction and maintenance therapies
- Dermatological conditions including acne vulgaris, alopecia areata, and chronic spontaneous urticaria
- Biosimilar development studies for established biologic treatments in autoimmune diseases
The center has established significant research capabilities in evaluating advanced immunomodulatory therapies, including IL-23 inhibitors, JAK inhibitors, TNF-alpha antagonists, and sphingosine-1-phosphate receptor modulators. With experience in complex trial designs involving combination therapies and long-term extension studies, Twoja Przychodnia demonstrates proficiency in assessing both clinical efficacy and safety outcomes across multiple therapeutic areas, contributing valuable data to the development of next-generation treatments for chronic inflammatory and autoimmune conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 10 therapeutic areas and 15 of 84 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 81 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 23 by active trials.
- 1UCB Biopharma3active
lock +22 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International7trials
lock +16 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Twoja Przychodnia Poznańskie Centrum Medyczne Sp. z o.o.
lock Showing 1 of 64 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Pharmacokinetic and Safety Study of Bimekizumab via Different Routes of Administration in Adults with Chronic Cutaneous Inflammation | UCB Biopharma | Phase I | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 84 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Guselkumab | 6 | Unknown | 2018-07-26 | 2022-11-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.